Sublimaze


What it is used for

SUBLIMAZE is indicated for analgesic action of short duration during anaesthetic periods, premedication, induction and maintenance, and in the immediate post-operative period (recovery room) as the need arises; use as a narcotic analgesic supplement in general and regional anaesthesia; administration with a neuroleptic such as droperidol injection as an anaesthetic premedication, for the induction of anaesthesia, and as an adjunct in the maintenance of general and regional anaesthesia.


How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

  • Store below 30 degrees Celsius
  • Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

  • Store below 30 degrees Celsius
  • Shelf lifetime is 3 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Pregnant or planning a pregnancy?

For the active ingredient fentanyl

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.


Do I need a prescription?

This medicine requires authorisation for prescription from your doctor. It is Schedule 8 : Controlled Drug.


Visual appearance

Clear colourless solution

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments